Diagnosis, severity assessment, and therapy evaluation of amyloidosis using amyloid PET imaiging (Continued study from 2020)
Not Applicable
Recruiting
- Conditions
- amyloidosis
- Registration Number
- JPRN-UMIN000042176
- Lead Sponsor
- Shinshu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Participant who doesn't agree to enroll the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intensity of tracer uptake in each organ.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What amyloid PET tracers are used in JPRN-UMIN000042176 for assessing amyloidosis severity and therapy response?
How does amyloid PET imaging compare to conventional methods in diagnosing and monitoring amyloidosis progression?
Which biomarkers correlate with amyloid PET imaging outcomes in JPRN-UMIN000042176 for amyloidosis subtypes?
What adverse events are reported with amyloid PET-guided therapies in JPRN-UMIN000042176 and their management?
Are there alternative amyloid PET tracers or combination therapies being evaluated for amyloidosis alongside JPRN-UMIN000042176?